News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Extends Review for Astellas Pharma Inc. (Jobs) Fungal Drug New Use
September 4, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Sept 3 (Reuters) - U.S. health authorities have extended by three months their review of Astellas Pharma Inc's application for fungal drug Mycamine to be used for additional indications, the company said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Asia
Astellas Pharma US, Inc.
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Parkinson’s disease
FDA Warns of Seizure Risk With Some Parkinson’s Drugs
March 23, 2026
·
2 min read
·
Tristan Manalac
Government
HHS Denies Disbandment of CDC Vaccine Advisory Group in Wake of Court Ruling
March 20, 2026
·
2 min read
·
Tristan Manalac
Approvals
Rhythm Bounces Back from Phase 3 Fail with FDA Nod for Rare Obesity Injection
March 20, 2026
·
2 min read
·
Tristan Manalac
Approvals
Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod
March 19, 2026
·
2 min read
·
Heather McKenzie